Abstract: The invention relates to a long-acting formulation of biopharmaceutical, more specifically an aptamer therapeutics. A branched PEGylated aptamer or a hyaluronic acid (HA) derivative of which degradation in vivo is regulated is linked by the bioconjugation with biopharmaceutical to produce the long-action formulation.

Abstract: Provided is a bone filling complex and method of preparing the same. The bone filling complex includes a matrix including a hydrogel-type hyaluronic acid derivative; and a bone derivative filling the matrix For example, the bone filling complex can be used to regenerate an injured alveolar bone.

Abstract: The present invention relates to a composition for preventing tissue adhesion which comprising a bio-compatible hyaluronic acid and a polymer compound. More specifically, the invention is a composition containing hyaluronic acid which has not been modified by a chemical crosslinking or other chemical modification a method for preparing the same, and a composition for adhesion prevention with superior efficacy. The composition of the present invention for preventing adhesion exhibits a physical barrier function and a new adhesion prevention function whereby thrombus formation, which is the basis of adhesion, is inhibited.

Abstract: The invention relates to a long-acting formulation of biopharmaceutical, more specifically an aptamer therapeutics. A branched PEGylated aptamer or a hyaluronic acid (HA) derivative of which degradation in vivo is regulated is linked by the bioconjugation with biopharmaceutical to produce the long-action formulation.

Abstract: Provided are a nanoporous membrane including a support; a first separation layer with a plurality of first nano-sized pores and a first matrix; and a second separation layer having a plurality of second pores respectively corresponding to the plurality of first pores of the first separation layer and a second matrix, and formed on the first separation layer, wherein a density of the plurality of the first pores and the second pores is equal to or greater than 1010/cm2, and a diameter of each of the second pores is less than that of the corresponding first pore, a process of fabricating the same, and a device for a controlled release of biopharmaceuticals including the nanoporous membrane. The device for a controlled release of biopharmaceuticals including the nanoporous membrane can release biopharmaceuticals at a constant rate for a long period of time regardless of the concentration of the biopharmaceuticals including in pharmaceuticals, and high flex and selectivity.

Abstract: Disclosed is a method for ablating hyaluronan-based hydrogels with X-rays, the method comprising the steps of: (a) preparing hyaluronan-based hydrogels; and (b) performing X-ray irradiation to the hyaluronan-based hydrogels to induce a degradation of the hyaluronan-based hydrogels by a gel-to-sol transition during the X-ray irradiation. Disclosed is also a method for fabricating three-dimensional microchannels of hyaluronan hydrogels with a finely tunable X-ray ablation technique.

Abstract: Disclosed is a method for ablating hyaluronan-based hydrogels with X-rays, the method comprising the steps of: (a) preparing hyaluronan-based hydrogels; and (b) performing X-ray irradiation to the hyaluronan-based hydrogels to induce a degradation of the hyaluronan-based hydrogels by a gel-to-sol transition during the X-ray irradiation. Disclosed is also a method for fabricating three-dimensional microchannels of hyaluronan hydrogels with a finely tunable X-ray ablation technique.

Abstract: The present invention aims to provide completely biodegradable and biocompatible sustained-release carriers for proteins or peptides, which allow encapsulation of the proteins or peptides at high encapsulation rates without inhibiting their biological activity. The present invention provides a method for preparing a sustained-release carrier, wherein in a solution in the presence of a protein or a peptide, a hyaluronic acid derivative having an unsaturated bond(s) or a mercapto group(s) introduced into hyaluronic acid is chemically crosslinked with a mercapto group-containing compound or an unsaturated bond-containing compound, respectively, to give a hydrogel. The method of the present invention enables efficient encapsulation of proteins or peptides while retaining their biological activity.

Abstract: The invention relates to a long-acting formulation of biopharmaceutical, more specifically an aptamer therapeutics. A branched PEGylated aptamer or a hyaluronic acid (HA) derivative of which degradation in vivo is regulated is linked by the bioconjugation with biopharmaceutical to produce the long-action formulation.

Abstract: Provided is a bone filling complex and a method of preparing the same. The bone filling complex includes a matrix including a hydrogel-type hyaluronic acid derivative; and a bone derivative filling the matrix, and thus adhesion can be prevented and excellent bone generation property can be obtained. For example, the bone filling complex can be used to an injured portion of alveolar bone to derive an regeneration of the alveolar bone.

Abstract: The invention relates to a novel bioconjugation protocol for peptide suitable for in vivo applications. Bioconjugation of the peptide to HA derivative increases its half life in circulation contributing for a high efficacy. More over, conjugate of HA derivative and peptide which is treated with hyaluronidase shows increased bioactivity. And also, in contrast to PEGylation, HA derivative can be conjugated with many numbers of peptide molecules per single HA derivative chain, which enables multiple action of peptide drugs.

Abstract: The present invention relates to a delivery system for nucleic acid using a cationic polymer conjugate, and more specifically relates to a delivery system for nucleic acid comprising a cationic polymer conjugate prepared by conjugating hyaluronic acid or its derivative and polyethyleneimine, and a composition of delivering a nucleic acid into mammalian cell comprising a complex of the nucleic acid and a cationic polymer conjugate with electrostatic binding.

Abstract: Provided are a nanoporous membrane including a support; a first separation layer with a plurality of first nano-sized pores and a first matrix; and a second separation layer having a plurality of second pores respectively corresponding to the plurality of first pores of the first separation layer and a second matrix, and formed on the first separation layer, wherein a density of the plurality of the first pores and the second pores is equal to or greater than 1010/cm2, and a diameter of each of the second pores is less than that of the corresponding first pore, a process of fabricating the same, and a device for a controlled release of biopharmaceuticals including the nanoporous membrane. The device for a controlled release of biopharmaceuticals including the nanoporous membrane can release biopharmaceuticals at a constant rate for a long period of time regardless of the concentration of the biopharmaceuticals including in pharmaceuticals, and high flex and selectivity.